Eintrag weiter verarbeiten
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optima...
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Journal of Clinical Oncology, 23, 2005, 16_suppl, S. 3028-3028 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Baselga, J. Rojo, F. Dumez, H. Mita, A. Takimoto, C. H. Tabernero, J. Dilea, C. Parker, K. Dugan, M. van Oosterom, A. T. Baselga, J. Rojo, F. Dumez, H. Mita, A. Takimoto, C. H. Tabernero, J. Dilea, C. Parker, K. Dugan, M. van Oosterom, A. T. |
|---|---|
| author |
Baselga, J. Rojo, F. Dumez, H. Mita, A. Takimoto, C. H. Tabernero, J. Dilea, C. Parker, K. Dugan, M. van Oosterom, A. T. |
| spellingShingle |
Baselga, J. Rojo, F. Dumez, H. Mita, A. Takimoto, C. H. Tabernero, J. Dilea, C. Parker, K. Dugan, M. van Oosterom, A. T. Journal of Clinical Oncology Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen Cancer Research Oncology |
| author_sort |
baselga, j. |
| spelling |
Baselga, J. Rojo, F. Dumez, H. Mita, A. Takimoto, C. H. Tabernero, J. Dilea, C. Parker, K. Dugan, M. van Oosterom, A. T. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3028 Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2005.23.16_suppl.3028 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4yMy4xNl9zdXBwbC4zMDI4 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4yMy4xNl9zdXBwbC4zMDI4 |
| institution |
DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Clinical Oncology (ASCO), 2005 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2005 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
baselga2005phaseistudyofaee788anovelmultitargetedinhibitoroferbbandvegfreceptorfamilytyrosinekinasesapharmacokineticpkpharmacodynamicpdstudytoidentifytheoptimaltherapeuticdoseregimen |
| publishDateSort |
2005 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_unstemmed |
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_full |
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_fullStr |
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_full_unstemmed |
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_short |
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_sort |
phase i study of aee788, a novel multitargeted inhibitor of erbb and vegf receptor family tyrosine kinases: a pharmacokinetic (pk)-pharmacodynamic (pd) study to identify the optimal therapeutic dose regimen |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3028 |
| publishDate |
2005 |
| physical |
3028-3028 |
| description |
|
| container_issue |
16_suppl |
| container_start_page |
3028 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
23 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792327856328540168 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:44:03.062Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Phase+I+study+of+AEE788%2C+a+novel+multitargeted+inhibitor+of+ErbB+and+VEGF+receptor+family+tyrosine+kinases%3A+A+pharmacokinetic+%28PK%29-pharmacodynamic+%28PD%29+study+to+identify+the+optimal+therapeutic+dose+regimen&rft.date=2005-06-01&genre=article&issn=1527-7755&volume=23&issue=16_suppl&spage=3028&epage=3028&pages=3028-3028&jtitle=Journal+of+Clinical+Oncology&atitle=Phase+I+study+of+AEE788%2C+a+novel+multitargeted+inhibitor+of+ErbB+and+VEGF+receptor+family+tyrosine+kinases%3A+A+pharmacokinetic+%28PK%29-pharmacodynamic+%28PD%29+study+to+identify+the+optimal+therapeutic+dose+regimen&aulast=van+Oosterom&aufirst=A.+T.&rft_id=info%3Adoi%2F10.1200%2Fjco.2005.23.16_suppl.3028&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792327856328540168 |
| author | Baselga, J., Rojo, F., Dumez, H., Mita, A., Takimoto, C. H., Tabernero, J., Dilea, C., Parker, K., Dugan, M., van Oosterom, A. T. |
| author_facet | Baselga, J., Rojo, F., Dumez, H., Mita, A., Takimoto, C. H., Tabernero, J., Dilea, C., Parker, K., Dugan, M., van Oosterom, A. T., Baselga, J., Rojo, F., Dumez, H., Mita, A., Takimoto, C. H., Tabernero, J., Dilea, C., Parker, K., Dugan, M., van Oosterom, A. T. |
| author_sort | baselga, j. |
| container_issue | 16_suppl |
| container_start_page | 3028 |
| container_title | Journal of Clinical Oncology |
| container_volume | 23 |
| description | |
| doi_str_mv | 10.1200/jco.2005.23.16_suppl.3028 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNS4yMy4xNl9zdXBwbC4zMDI4 |
| imprint | American Society of Clinical Oncology (ASCO), 2005 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2005 |
| institution | DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:44:03.062Z |
| match_str | baselga2005phaseistudyofaee788anovelmultitargetedinhibitoroferbbandvegfreceptorfamilytyrosinekinasesapharmacokineticpkpharmacodynamicpdstudytoidentifytheoptimaltherapeuticdoseregimen |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 3028-3028 |
| publishDate | 2005 |
| publishDateSort | 2005 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Baselga, J. Rojo, F. Dumez, H. Mita, A. Takimoto, C. H. Tabernero, J. Dilea, C. Parker, K. Dugan, M. van Oosterom, A. T. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3028 Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen Journal of Clinical Oncology |
| spellingShingle | Baselga, J., Rojo, F., Dumez, H., Mita, A., Takimoto, C. H., Tabernero, J., Dilea, C., Parker, K., Dugan, M., van Oosterom, A. T., Journal of Clinical Oncology, Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen, Cancer Research, Oncology |
| title | Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_full | Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_fullStr | Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_full_unstemmed | Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_short | Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| title_sort | phase i study of aee788, a novel multitargeted inhibitor of erbb and vegf receptor family tyrosine kinases: a pharmacokinetic (pk)-pharmacodynamic (pd) study to identify the optimal therapeutic dose regimen |
| title_unstemmed | Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3028 |